Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Effects of Akkermansia Muciniphila-Based Probiotics on Autonomic and Vascular Function

12 listopada 2026 zaktualizowane przez: University of Minnesota

Effects of Akkermansia Muciniphila-Based Probiotics on Autonomic and Vascular Function in Humans

This randomized, double-blind, placebo-controlled pilot study will investigate the effects of an Akkermansia muciniphila-based probiotic supplement, Panthea Core, on autonomic and vascular function in postmenopausal women with hypertension.

Up to 60 participants aged 45 to 65 years will be enrolled to obtain approximately 40 evaluable datasets. Participants will be randomly assigned to receive Panthea Core or a matched placebo capsule daily for 12 weeks.

The study will evaluate safety, tolerability, menopausal symptoms, and changes in autonomic and vascular physiology. The primary mechanistic outcome is muscle sympathetic nerve activity (MSNA), measured using microneurography. Secondary physiological outcomes include heart rate variability, baroreflex sensitivity, endothelial function assessed by flow-mediated dilation, and blood pressure.

Additional assessments will include sleep, menopausal symptoms, mood, cognitive function, circulating metabolic markers, and gut microbiome composition. Participants will complete baseline and post-intervention assessments, with additional safety monitoring throughout supplementation and approximately one month after the intervention.

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Szczegółowy opis

Akkermansia muciniphila is a bacterium normally found in the human gastrointestinal tract that has been associated with metabolic and immune regulation. Previous research suggests that changes in Akkermansia muciniphila abundance may be related to blood pressure regulation, autonomic nervous system function, and vascular health. However, the effects of direct supplementation on human autonomic and endothelial physiology have not been adequately characterized.

This pilot study will evaluate the effects of a 12-week Akkermansia muciniphila-based probiotic supplement, Panthea Core, in postmenopausal women with hypertension. Hypertension is used as a physiological model of autonomic and vascular dysregulation, rather than as a treatment endpoint.

Participants will be randomized to Panthea Core or matched placebo in a double-blind, parallel-group design. The study plans to recruit up to 60 participants to obtain approximately 40 evaluable datasets.

Participants will complete three in-person study visits, including informed consent and two physiological assessment visits. During the baseline and post-intervention assessments, autonomic nervous system activity will be evaluated using microneurography to measure muscle sympathetic nerve activity, electrocardiography to assess heart rate variability, and physiological testing to assess baroreflex sensitivity.

Vascular endothelial function will be assessed using brachial artery flow-mediated dilation. Blood pressure and heart rate will also be measured.

Additional evaluations include laboratory safety measurements, metabolic and hormonal biomarkers, menopausal symptoms, sleep quality, mood, cognition, anthropometric measurements, dietary intake, and stool-based microbiome profiling.

Participants will take their assigned supplement or placebo daily for 12 weeks. Adverse events and gastrointestinal tolerability will be assessed through biweekly questionnaires and participant-initiated reporting. A follow-up contact approximately one month after the final testing visit will assess additional symptoms and adverse events.

The study is intended to generate preliminary mechanistic, safety, and tolerability data to inform the design of subsequent clinical research. As a pilot study, it is not powered to establish definitive treatment efficacy.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

60

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

  • Nazwa: Manda Keller-Ross
  • Numer telefonu: 612-625-3175
  • E-mail: kell0529@umn.edu

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

    • Minnesota
      • Minneapolis, Minnesota, Stany Zjednoczone, 55455
        • University of Minnesota - Children's Rehabilitation Center
        • Kontakt:
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

45 lat do 65 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Kobieta

Opis

Inclusion Criteria:

  • Female individuals, assigned female sex at birth, aged 45 to 65 years.
  • Clinician-diagnosed hypertension, either controlled or uncontrolled.
  • Postmenopausal status, defined as at least 12 months without menstruation or prior surgical removal of the ovaries.
  • Willing and able to provide informed consent.

Exclusion Criteria:

  • Nicotine/tobacco, probiotic, or antibiotic use within the previous six months.
  • Body mass index of 40 kg/m² or greater.
  • Use of hormonal contraceptives or systemic exogenous hormones.
  • Diagnosis of diabetes.
  • Respiratory disease other than well-controlled asthma.
  • Severe neurological conditions, including traumatic brain injury or stroke.
  • Existing endocrine abnormalities.
  • History of chemotherapy.
  • Surgery within the preceding six months.
  • Autoimmune disorders.
  • History of organ transplantation.
  • Digestive disorders, including active or unstable gastrointestinal disease, major gastrointestinal surgery, or motility disorders.
  • Immunosuppressive or glucocorticoid therapy.
  • Chronic illnesses that preclude participation at the investigator's discretion.
  • Intermittent fasting with unwillingness or inability to complete a four-week washout period before enrollment.
  • Inability to speak, read, or understand English.
  • Inability to provide informed consent.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Podstawowa nauka
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Panthea Core Supplementation

Participants randomized to this group will receive one daily oral capsule of Panthea Core containing live Akkermansia muciniphila and additional dietary supplement ingredients for 12 weeks. Participants will undergo baseline and post-intervention assessments of autonomic and vascular function, safety, and related physiological outcomes.

Panthea Core is an oral probiotic formulation containing live Akkermansia muciniphila (approximately 1 × 10^8 active fluorescence units), pyridoxal-5'-phosphate (10 mg), spermidine trihydrochloride (1.2 mg), and 3,3'-diindolylmethane (100 mg). Participants will take the formulation once daily for 12 weeks. Study product will be distributed through the Investigational Drug Services Pharmacy.

Inne nazwy:
  • Akkermansia muciniphila-Based Probiotic
  • Panthea Core Supplementation
Komparator placebo: Placebo

Participants randomized to this group will receive a matched placebo capsule daily for 12 weeks. Participants will undergo the same baseline and post-intervention assessments as those assigned to Panthea Core.

Participants will receive a matched oral placebo capsule administered once daily for 12 weeks. The placebo will be supplied by Panthea Inc. and dispensed through the Investigational Drug Services Pharmacy.

Inne nazwy:
  • Placebo
  • Placebo for Panthea Core

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in Muscle Sympathetic Nerve Activity (MSNA)
Ramy czasowe: Baseline to 12 weeks

Muscle sympathetic nerve activity will be measured using microneurography of the fibular nerve. MSNA burst frequency, expressed as bursts per minute, will be assessed at baseline and after 12 weeks of Panthea Core or placebo supplementation. Changes in MSNA will be compared between treatment groups.

Baseline to 12 weeks
Incidence of Adverse Events
Ramy czasowe: From initiation of supplementation through approximately 4 weeks after the 12-week intervention

Adverse events and serious adverse events will be monitored throughout the intervention through biweekly REDCap questionnaires, participant-initiated reports, and post-intervention follow-up. The incidence and nature of adverse events will be summarized by treatment group to evaluate the safety and tolerability of Panthea Core.

From initiation of supplementation through approximately 4 weeks after the 12-week intervention
Change in Comprehensive Metabolic Panel Laboratory Measures
Ramy czasowe: Baseline and 12 weeks

Safety will be evaluated through changes in comprehensive metabolic panel laboratory measurements, including renal function, liver function, and electrolyte measurements. Laboratory results will be assessed at baseline and after 12 weeks of supplementation and summarized by treatment group.

Baseline and 12 weeks
Supplement Adherence
Ramy czasowe: Throughout the 12-week intervention

Adherence to daily Panthea Core or placebo supplementation will be monitored throughout the intervention using participant-reported information collected through biweekly REDCap questionnaires. Adherence will be summarized descriptively, with a protocol target of at least 80%.

Throughout the 12-week intervention
Study Retention
Ramy czasowe: From enrollment through completion of the 12-week intervention

Study retention will be assessed as the proportion of enrolled participants who complete the planned intervention and post-intervention assessments. The protocol specifies a retention target of at least 75%.

From enrollment through completion of the 12-week intervention

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change in Flow-Mediated Dilation (FMD)
Ramy czasowe: Baseline to 12 weeks

Endothelial function will be assessed using brachial artery ultrasound flow-mediated dilation, expressed as percentage change in vessel diameter following temporary forearm occlusion.

Baseline to 12 weeks
Change in Heart Rate Variability (HRV)
Ramy czasowe: Baseline to 12 weeks

Cardiovagal modulation will be evaluated using time-domain and frequency-domain measures derived from electrocardiogram recordings.

Baseline to 12 weeks
Change in Cardiovagal Baroreflex Sensitivity
Ramy czasowe: Baseline to 12 weeks

Cardiovagal baroreflex sensitivity will be assessed using changes in ECG R-R intervals relative to changes in systolic blood pressure, expressed in ms/mmHg.

Baseline to 12 weeks
Change in Sympathetic Baroreflex Sensitivity
Ramy czasowe: Baseline to 12 weeks

Sympathetic baroreflex sensitivity will be evaluated using changes in MSNA relative to diastolic blood pressure, expressed in bursts/100 heartbeats/mmHg as described in the protocol.

Baseline to 12 weeks
Change in Blood Pressure
Ramy czasowe: Baseline to 12 weeks

Systolic and diastolic blood pressure will be measured at baseline and after the 12-week intervention to assess changes in blood pressure as a physiological parameter.

Baseline to 12 weeks
Change in Menopause-Specific Quality of Life
Ramy czasowe: Baseline to 12 weeks

Menopausal symptoms and quality of life will be assessed using the Menopause-Specific Quality of Life (MENQOL) questionnaire, including vasomotor, physical, psychosocial, and sexual domains.

Baseline to 12 weeks
Change in Depressive Symptoms (PHQ-9)
Ramy czasowe: Baseline to 12 weeks

Depressive symptoms will be evaluated using the nine-item Patient Health Questionnaire (PHQ-9).

Baseline to 12 weeks
Change in Insomnia Severity (ISI)
Ramy czasowe: Baseline to 12 weeks

Insomnia symptoms will be assessed using the seven-item Insomnia Severity Index.

Baseline to 12 weeks
Change in Subjective Sleep Quality (PSQI)
Ramy czasowe: Baseline to 12 weeks

(PSQI) Subjective sleep quality and disturbances will be assessed using the Pittsburgh Sleep Quality Index.

Baseline to 12 weeks
Change in Objective Sleep Parameters
Ramy czasowe: Baseline to 12 weeks

Sleep will be measured using WatchPAT ONE-M monitoring before baseline and post-intervention physiological testing.

Baseline to 12 weeks
Change in Cognitive Function (MoCA)
Ramy czasowe: Baseline to 12 weeks

Cognitive function will be evaluated using Montreal Cognitive Assessment scores before and after supplementation.

Baseline to 12 weeks
Change in Gut Microbiome Composition
Ramy czasowe: Baseline to 12 weeks

Fecal microbiome sequencing will be used to evaluate changes in microbial composition and the abundance of Akkermansia muciniphila after supplementation.

Baseline to 12 weeks

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Manda Keller-Ross, University of Minnesota

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 lutego 2027

Zakończenie podstawowe (Szacowany)

31 stycznia 2030

Ukończenie studiów (Szacowany)

31 stycznia 2030

Daty rejestracji na studia

Pierwszy przesłany

12 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

12 listopada 2026

Pierwszy wysłany (Rzeczywisty)

18 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

18 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

12 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • PT-2026-34798

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj